Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: A conjoint analysis

MEDTAP International Inc, Bethesda, Maryland, USA.
Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology (Impact Factor: 2.6). 10/2004; 93(4):345-50. DOI: 10.1016/S1081-1206(10)61393-2
Source: PubMed


Sensory attributes of intranasal corticosteroid (INS) products vary.
To evaluate patient preferences for INS sensory attributes and the degree to which attributes influence patients' willingness to adhere to therapy.
We conducted a cross-sectional study with 120 individuals across 4 US allergy/immunology clinics. Respondents chose between pairs of hypothetical INSs differing in sensory attribute composition. We measured the strength of preferences for 6 sensory attributes (smell, taste, aftertaste, throat rundown, nose runout, and feel of spray in nose or throat). Preferences were measured for 3 intensity levels of each sensory attribute (eg, no taste, weak taste, and strong taste). Other outcomes included an importance score for each sensory attribute and patients' willingness to adhere to therapy with an INS with the lowest intensity levels of each sensory attribute vs one with moderate intensity levels.
Preferences decreased with increasing intensity levels of each sensory attribute. Aftertaste was the most important attribute in 28% of patients, taste in 19%, throat rundown in 18%, nose runout in 12%, smell in 11%, and feel of spray in 7%. If instructed to take an INS daily for 3 months, 77% of patients stated that they would definitely be able to follow their physician's advice (willingness to adhere) if given one containing the lowest level of each sensory attribute vs 4% if given one having moderate levels (P < .01).
Patient preferences are inversely related to increasing intensity levels of sensory attributes and affect patients' willingness to adhere to therapy. Application of patient preferences when selecting INSs could improve adherence.

10 Reads
  • Source
    • "Patients reported lack of efficacy (37%), diminished effectiveness over time (35%), lack of 24-hour relief (32%), and side effects (25%) from the medication as reasons why they discontinued treatment.14 Mahadevia et al reported that patients’ willingness to adhere to physician advice would significantly improve with more favorable sensory attributes.15 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Allergic rhinitis affects 10%–20% of the US population. Its chronic nature, combined with patients’ perceptions of safety/efficacy, administration, and sensory attributes of nasal sprays (corticosteroids), impact patient adherence to therapy. The purpose of this study was to develop a measure of experience with and preference for corticosteroid therapy for treatment of allergic rhinitis. Methods: Questionnaire development was conducted through qualitative research including concept elicitation and content testing in 153 patients with allergic rhinitis. Patient focus groups (n = 66), in conjunction with content confirmation and saturation in additional groups (n = 87), provided research data. A literature-based conceptual framework was incorporated into the interview guide. An iterative process of data collection, analysis, and theory development yielded the conceptual framework. Results: Consistent comments from the focus groups combined with those from cognitive debriefing interviews led to the incorporation of 14 finalized attributes into the Experience with Allergic Rhinitis Nasal Spray Questionnaire (EARNS-Q) items. Between the first and second cognitive debriefing interviews, researchers revised the EARNS-Q for retesting. Face and content validity tests indicated that the items, responses, and instructions were understood by study participants. The EARNS-Q is comprised of two modules that measure patient experience with nasal sprays (experience module), and patient preference for a nasal spray relative to another (preference module). Conclusion: The EARNS-Q accurately measured patient experience with and preference for nasal sprays used in treating allergic rhinitis. A potential application of this questionnaire may be as a patient-reported outcomes endpoint in clinical trials of intranasal corticosteroids in patients with allergic rhinitis.
    Patient Related Outcome Measures 07/2011; 2:2-119. DOI:10.2147/PROM.S19195
  • Source
    • "Important sensory attributes include minimal odor and irritant effect, absent taste and product moistness. It has been shown that the intensity of such sensory components is inversely correlated with preference.84 Sensory attributes vary considerably between current market preparations.84,85,89 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Seasonal allergic rhinitis (SAR) is increasing in prevalence such that 1 in 4 persons is affected in the UK. It represents a considerable burden of disease since in a significant proportion of individuals the severity of nasal-ocular symptoms has an important effect on daily activity, performance and quality of life. Intranasal steroids (INS) form the mainstay of treatment, having been shown in meta-analyses to be superior to oral antihistamines, intranasal antihistamines and anti-leukotrienes. Fluticasone propionate is an established INS for the treatment of rhinitis, including SAR. Its favorable pharmacological profile combining high local efficacy with low systemic bioavailability has established fluticasone propionate as an effective intervention. The more recent introduction of structurally related fluticasone furoate with similar but enhanced pharmacological characteristics with a novel delivery device may confer further therapeutic advantages.
    Journal of Asthma and Allergy 06/2010; 3:19-28.
  • Source
    • "Perception of taste, anterior and posterior nasal dripping of spray, and smell are important criteria in patient preference for the use of INCS (Mahadevia et al 2004). BKC has an unpleasant bitter taste; budesonide (which does not contain BKC) was preferred over fl uticasone propionate on the basis of taste (Shah et al 2003), and similarly, triamcinolone acetonide was preferred over fl uticasone propionate and mometasone furoate (Bachert et al 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ciclesonide is a novel corticosteroid which is optimized for topical use. It is a pro-drug which is activated locally in the airway mucosa, lipid-conjugated for local retention, and has very high protein binding in circulation leading to low systemic bioavailability. These characteristics should lead to highly selective activity with reduced local and systemic side effects. It has been established as an inhaled medication for asthma and has also been shown in double-blind trials to be efficacious for the treatment of seasonal and perennial allergic rhinitis. However no data have yet demonstrated superiority over existing nasal topical corticosteroids, either in terms of efficacy or adverse effects, and trials have not yet clearly shown efficacy in rhinitis in children. Therefore the place of ciclesonide in the treatment of allergic rhinitis relative to other existing products remains unclear.
    Journal of Asthma and Allergy 11/2008; 1(1):49-54.
Show more

Similar Publications